in line with reductions in HbA 1creported in a 28-day phase 2 study of /H110020.7 to /H110021.1% (8); however, due to differences in study designs, inclusion criteria, anddosing regimens, it is difﬁcult to directlycompare these results. The proinsulin-to-insulin ratio improved over the 30 weeksof exenatide treatment, suggesting an im-provement in /H9252-cell function (37). Exenatide treatment at a ﬁxed dose of 10/H9262g was associated with reductions in